Cargando…

Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats

In this study, the in vitro and in vivo bone formation behavior of mesoporous bioactive glass (MBG) particles incorporated in a pasty strontium-containing calcium phosphate bone cement (pS100G10) was studied in a metaphyseal fracture-defect model in ovariectomized rats and compared to a plain pasty...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Seemun, Thormann, Ulrich, Kramer, Inga, Sommer, Ursula, Budak, Matthäus, Schumacher, Matthias, Bernhardt, Anne, Lode, Anja, Kern, Christine, Rohnke, Marcus, Heiss, Christian, Lips, Katrin S., Gelinsky, Michael, Alt, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604136/
https://www.ncbi.nlm.nih.gov/pubmed/37892933
http://dx.doi.org/10.3390/bioengineering10101203
_version_ 1785126764320653312
author Ray, Seemun
Thormann, Ulrich
Kramer, Inga
Sommer, Ursula
Budak, Matthäus
Schumacher, Matthias
Bernhardt, Anne
Lode, Anja
Kern, Christine
Rohnke, Marcus
Heiss, Christian
Lips, Katrin S.
Gelinsky, Michael
Alt, Volker
author_facet Ray, Seemun
Thormann, Ulrich
Kramer, Inga
Sommer, Ursula
Budak, Matthäus
Schumacher, Matthias
Bernhardt, Anne
Lode, Anja
Kern, Christine
Rohnke, Marcus
Heiss, Christian
Lips, Katrin S.
Gelinsky, Michael
Alt, Volker
author_sort Ray, Seemun
collection PubMed
description In this study, the in vitro and in vivo bone formation behavior of mesoporous bioactive glass (MBG) particles incorporated in a pasty strontium-containing calcium phosphate bone cement (pS100G10) was studied in a metaphyseal fracture-defect model in ovariectomized rats and compared to a plain pasty strontium-containing calcium phosphate bone cement (pS100) and control (empty defect) group, respectively. In vitro testing showed good cytocompatibility on human preosteoblasts and ongoing dissolution of the MBG component. Neither the released strontium nor the BMG particles from the pS100G10 had a negative influence on cell viability. Forty-five female Sprague–Dawley rats were randomly assigned to three different treatment groups: (1) pS100 (n = 15), (2) pS100G10 (n = 15), and (3) empty defect (n = 15). Twelve weeks after bilateral ovariectomy and multi-deficient diet, a 4 mm wedge-shaped fracture-defect was created at the metaphyseal area of the left femur in all animals. The originated fracture-defect was substituted with pS100 or pS100G10 or left empty. After six weeks, histomorphometrical analysis revealed a statistically significant higher bone volume/tissue volume ratio in the pS100G10 group compared to the pS100 (p = 0.03) and empty defect groups (p = 0.0001), indicating enhanced osteoconductivity with the incorporation of MBG. Immunohistochemistry revealed a significant decrease in the RANKL/OPG ratio for pS100 (p = 0.004) and pS100G10 (p = 0.003) compared to the empty defect group. pS100G10 showed a statistically higher expression of BMP-2. In addition, a statistically significant higher gene expression of alkaline phosphatase, osteoprotegerin, collagen1a1, collagen10a1 with a simultaneous decrease in RANKL, and carbonic anhydrase was seen in the pS100 and pS100G10 groups compared to the empty defect group. Mass spectrometric imaging by time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the release of Sr(2+) ions from both pS100 and pS100G10, with a gradient into the interface region. ToF-SIMS imaging also revealed that resorption of the MBG particles allowed for new bone formation in cement pores. In summary, the current work shows better bone formation of the injectable pasty strontium-containing calcium phosphate bone cement with incorporated mesoporous bioactive glass compared to the bioactive-free bone cement and empty defects and can be considered for clinical application for osteopenic fracture defects in the future.
format Online
Article
Text
id pubmed-10604136
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106041362023-10-28 Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats Ray, Seemun Thormann, Ulrich Kramer, Inga Sommer, Ursula Budak, Matthäus Schumacher, Matthias Bernhardt, Anne Lode, Anja Kern, Christine Rohnke, Marcus Heiss, Christian Lips, Katrin S. Gelinsky, Michael Alt, Volker Bioengineering (Basel) Article In this study, the in vitro and in vivo bone formation behavior of mesoporous bioactive glass (MBG) particles incorporated in a pasty strontium-containing calcium phosphate bone cement (pS100G10) was studied in a metaphyseal fracture-defect model in ovariectomized rats and compared to a plain pasty strontium-containing calcium phosphate bone cement (pS100) and control (empty defect) group, respectively. In vitro testing showed good cytocompatibility on human preosteoblasts and ongoing dissolution of the MBG component. Neither the released strontium nor the BMG particles from the pS100G10 had a negative influence on cell viability. Forty-five female Sprague–Dawley rats were randomly assigned to three different treatment groups: (1) pS100 (n = 15), (2) pS100G10 (n = 15), and (3) empty defect (n = 15). Twelve weeks after bilateral ovariectomy and multi-deficient diet, a 4 mm wedge-shaped fracture-defect was created at the metaphyseal area of the left femur in all animals. The originated fracture-defect was substituted with pS100 or pS100G10 or left empty. After six weeks, histomorphometrical analysis revealed a statistically significant higher bone volume/tissue volume ratio in the pS100G10 group compared to the pS100 (p = 0.03) and empty defect groups (p = 0.0001), indicating enhanced osteoconductivity with the incorporation of MBG. Immunohistochemistry revealed a significant decrease in the RANKL/OPG ratio for pS100 (p = 0.004) and pS100G10 (p = 0.003) compared to the empty defect group. pS100G10 showed a statistically higher expression of BMP-2. In addition, a statistically significant higher gene expression of alkaline phosphatase, osteoprotegerin, collagen1a1, collagen10a1 with a simultaneous decrease in RANKL, and carbonic anhydrase was seen in the pS100 and pS100G10 groups compared to the empty defect group. Mass spectrometric imaging by time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the release of Sr(2+) ions from both pS100 and pS100G10, with a gradient into the interface region. ToF-SIMS imaging also revealed that resorption of the MBG particles allowed for new bone formation in cement pores. In summary, the current work shows better bone formation of the injectable pasty strontium-containing calcium phosphate bone cement with incorporated mesoporous bioactive glass compared to the bioactive-free bone cement and empty defects and can be considered for clinical application for osteopenic fracture defects in the future. MDPI 2023-10-16 /pmc/articles/PMC10604136/ /pubmed/37892933 http://dx.doi.org/10.3390/bioengineering10101203 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ray, Seemun
Thormann, Ulrich
Kramer, Inga
Sommer, Ursula
Budak, Matthäus
Schumacher, Matthias
Bernhardt, Anne
Lode, Anja
Kern, Christine
Rohnke, Marcus
Heiss, Christian
Lips, Katrin S.
Gelinsky, Michael
Alt, Volker
Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title_full Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title_fullStr Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title_full_unstemmed Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title_short Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats
title_sort mesoporous bioactive glass-incorporated injectable strontium-containing calcium phosphate cement enhanced osteoconductivity in a critical-sized metaphyseal defect in osteoporotic rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604136/
https://www.ncbi.nlm.nih.gov/pubmed/37892933
http://dx.doi.org/10.3390/bioengineering10101203
work_keys_str_mv AT rayseemun mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT thormannulrich mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT krameringa mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT sommerursula mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT budakmatthaus mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT schumachermatthias mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT bernhardtanne mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT lodeanja mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT kernchristine mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT rohnkemarcus mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT heisschristian mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT lipskatrins mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT gelinskymichael mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats
AT altvolker mesoporousbioactiveglassincorporatedinjectablestrontiumcontainingcalciumphosphatecementenhancedosteoconductivityinacriticalsizedmetaphysealdefectinosteoporoticrats